Sarepta’s disappointing data put the FDA in a difficult spot

Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy missed its primary goal in a pivotal study, but the company still intends to push for a broader FDA approval, saddling regulators with a difficult decision.